According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
Separately, Cowen and Company reaffirmed a buy rating on shares of Beigene in a research report on Monday, June 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Beigene presently has an average rating of Buy and an average price target of $40.00.
Beigene (NASDAQ:BGNE) opened at 31.18 on Monday. Beigene has a 52 week low of $22.51 and a 52 week high of $35.60. The company has a 50-day moving average of $29.43 and a 200 day moving average of $29.00. The firm’s market cap is $1.03 billion.
Beigene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 10th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.05. The business earned $0.40 million during the quarter, compared to analysts’ expectations of $2.08 million. The company’s revenue for the quarter was down 71.4% compared to the same quarter last year. On average, equities analysts predict that Beigene will post ($3.45) earnings per share for the current year.
In other news, Director Donald W. Glazer sold 67,252 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $31.42, for a total transaction of $2,113,057.84. Following the transaction, the director now directly owns 4,882,000 shares of the company’s stock, valued at $153,392,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Boxer Capital LLC raised its position in shares of Beigene by 18.4% in the second quarter. Boxer Capital LLC now owns 493,630 shares of the company’s stock worth $14,710,000 after buying an additional 76,751 shares during the period. Vident Investment Advisory LLC purchased a new position in shares of Beigene during the second quarter valued at $678,000. FMR LLC boosted its position in shares of Beigene by 34.0% in the second quarter. FMR LLC now owns 2,300,337 shares of the company’s stock valued at $68,550,000 after buying an additional 583,277 shares in the last quarter. Board of Trustees of The Leland Stanford Junior University purchased a new position in shares of Beigene during the second quarter valued at $1,490,000. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Beigene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock valued at $191,000 after buying an additional 2,589 shares in the last quarter.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.